lung

Giorgio Scagliotti Robert Pirker GIORGIO SCAGLIOTTI, University of Turin ROBERT PIRKER, Medical University of Vienna A heated debate took place at the European Congress on Lung Cancer in Turin between

Nick Thatcher NICK THATCHER, Christie Hospital, Manchester There is a proven benefit in survival if you give your patients cis-platinum based chemotherapy after resection for non-small cell lung cance

Egbert Smit EGBERT SMIT, Free University of Amsterdam There are a number of promising new molecular targets for lung cancer chemotherapy which were discussed at the Turin congress by Egbert Smit. He t

Silvia Novello SILVIA NOVELLO, University of Turin Future improvements in drug treatment of lung cancer may be made by inhibiting more than one tyrosine kinase simultaneously. So said Silvia Novello w

Christian Manegold Nick Thatcher Christian Manegold, Heidelberg University Medical Center, Manheim Nick Thatcher, Christie Hospital, Manchester Is bevacizumab a new standard of care for patients with

Jean-Yves Douillard Gordon McVie REFERENCE: Abstracts: 6507 & 2LB, ECCO 14, The European Cancer Conference, Barcelona, 23 Р27 September 2007 JEAN-YVES DOUILLARD, Centre Ren̩ Gauducheau, N

George Sopko

Jose Baselga Gordon McVie REFERENCE: ABSTRACT 2030, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007 JOSE BASELGA, Vall d’Hebron University Hospital, Barcelona CO

Clifford Hudis Mark Einstein Tony Greco James Berenson Edward Ambinder Breast Cancer: HER2 Still a Useful Target After Trastuzumab Resistance REFERENCE: Chemotherapy Foundation Symposium XXIV 8-11 Nov

Gordon McVie Martine Piccart Bella Kaufman Jean-Yves Douillard ESMO Congress Reviewed GORDON MCVIE, European Institute of Oncology, Milan In Istanbul, Gordon McVie gave his opinion about the achieveme

Mark Socinski Bruce Johnson Neil Shah Doug Smith Sunitinib Multi-Targeted Oral Anti-Angiogenic Therapy Responses in Lung Cancer REFERENCE: Abstract 7001 Mark A. Socinski, Univerisity of North Carolina